2022年分子遗传病理学新进展：免疫检查点抑制剂生物标志物与特定实体瘤
What's new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors.
作者信息
Tsang Patricia C, Chen Guoli
机构信息
MedStar Washington Hospital Center, Pathology & Laboratory Medicine, Washington, DC, USA.
Geisinger Medical Laboratories, Geisinger Health, Danville, Pennsylvania, USA.
出版信息
J Pathol Transl Med. 2022 Mar;56(2):113-114. doi: 10.4132/jptm.2022.01.25. Epub 2022 Mar 11.
Abstract
Predictive biomarker testing plays a critical role in targeted immuno-oncology, including the use of immune checkpoint inhibitors (ICI) for various solid tumors. Molecular advancements in cancers of the breast, kidney and brain have continued to propel tumor classification and precision therapy.
摘要
预测性生物标志物检测在靶向免疫肿瘤学中发挥着关键作用，包括将免疫检查点抑制剂（ICI）用于各种实体瘤。乳腺癌、肾癌和脑癌的分子进展持续推动肿瘤分类和精准治疗。
Zotero 插件